| Company Name: |
Cool Pharm, Ltd
|
| Tel: |
021-58581007 18019463053 |
| Email: |
sales@coolpharm.com |
| Products Intro: |
Product Name:PPDA-001
CAS:1805833-75-3
Purity:95.0% Package:10g;25g;100g;500g;1kg;5kg;10kg
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:ICEC-0942
CAS:1805833-75-3
Purity:95% Package:$499/10mg
|
| Company Name: |
TaiChem Taizhou Limited
|
| Tel: |
052386810091 |
| Email: |
zcwy9518@yeah.net |
| Products Intro: |
Product Name:(3R,4R)-4-(((7-(benzylamino)-3-isopropylpyrazolo[1,5-a]pyrimidin-5-yl)amino)methyl)piperidin-3-ol
CAS:1805833-75-3
Purity:95% Package:1G;2G;5G
|
|
| | 3-Piperidinol, 4-[[[3-(1-methylethyl)-7-[(phenylmethyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]-, (3R,4R)- Basic information |
| Product Name: | 3-Piperidinol, 4-[[[3-(1-methylethyl)-7-[(phenylmethyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]-, (3R,4R)- | | Synonyms: | 3-Piperidinol, 4-[[[3-(1-methylethyl)-7-[(phenylmethyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]-, (3R,4R)-;PPDA-001;ICEC0942 (CT7001) Free base;ICEC-0942;CT7001);ICEC 0942
(ICEC0942;Samuraciclib;(3R,4R)-4-(((7-(benzylamino)-3-isopropylpyrazolo[1,5-a]pyrimidin-5-yl)amino)methyl)piperidin-3-ol | | CAS: | 1805833-75-3 | | MF: | C22H30N6O | | MW: | 394.51 | | EINECS: | | | Product Categories: | | | Mol File: | 1805833-75-3.mol | ![3-Piperidinol, 4-[[[3-(1-methylethyl)-7-[(phenylmethyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]-, (3R,4R)- Structure](CAS/20180601/GIF/1805833-75-3.gif) |
| | 3-Piperidinol, 4-[[[3-(1-methylethyl)-7-[(phenylmethyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]-, (3R,4R)- Chemical Properties |
| density | 1.30±0.1 g/cm3(Predicted) | | pka | 14.69±0.40(Predicted) |
| | 3-Piperidinol, 4-[[[3-(1-methylethyl)-7-[(phenylmethyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]-, (3R,4R)- Usage And Synthesis |
| Uses | Samuraciclib can be used to treat tuberous sclerosis complex using cyclin dependent kinase 7 (CDK7) inhibitors. | | in vivo | Samuraciclib (ICEC0942; 100 mg/kg; oral gavage; daily; for 14 days; female nu/nu-BALB/c athymic nude mice) treatment inhibits tumor growth by 60% at day 14, and is accompanied by highly significant reductions in PolII Ser2 and Ser5 phosphorylation in PBMCs and in tumors[1].
The combination of Samuraciclib (ICEC0942) and ICI 47699 treatment shows complete growth arrest of estrogen receptor (ER)-positive tumor xenografts[1]. | Animal Model: | Female nu/nu-BALB/c athymic nude mice (7-week old) with MCF7 cells[1]. | | Dosage: | 100 mg/kg | | Administration: | Oral gavage; daily; for 14 days | | Result: | At day 14, tumor growth was inhibited by 60%. |
| | IC 50 | CDK7/CycH/MAT1: 41 nM (IC50); CDK2/cycE1: 578 nM (IC50); CDK1: 1.8 μM (IC50); CDK4: 49 μM (IC50); CDK5: 9.4 μM (IC50); CDK6: 34 μM (IC50); CDK9: 1.2 μM (IC50) |
| | 3-Piperidinol, 4-[[[3-(1-methylethyl)-7-[(phenylmethyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]-, (3R,4R)- Preparation Products And Raw materials |
|